ID   SK-BR-5
AC   CVCL_5217
SY   SK-Br-5; SKBR-5; SKBr5; SkBr5; SKBR5
DR   cancercelllines; CVCL_5217
DR   Cosmic; 997936
DR   Cosmic; 1046938
DR   Cosmic; 1287912
DR   Cosmic; 1289406
DR   DepMap; ACH-002329
DR   GEO; GSM421884
DR   GEO; GSM1661989
DR   IARC_TP53; 24347
DR   PharmacoDB; SKBR5_1384_2019
DR   Wikidata; Q54953625
RX   PubMed=6582512;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=19593635;
RX   PubMed=23601657;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; c.532-1G>C; ClinVar=VCV000406644; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Homozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Asp (c.482C>A); ClinVar=VCV000422295; Zygosity=Unspecified (PubMed=16541312).
CC   Omics: miRNA expression profiling.
CC   Omics: Transcriptome analysis by microarray.
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
//